drugset
drugset / Trial / NCT00495378

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

NCT00495378 ↗

Phase 4 Terminated 25 enrolled Ortho Biotech Products, L.P.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to determine if alternate dosing of Epoetin alfa was effective in maintaining hemoglobin levels in patients with chemotherapy related anemia.

Timeline

Start
2002-11
Primary completion
—
Completion
2003-03

Outcome

Outcome not reported

Stopped (Enrollment): “This study was stopped due to slow enrollment after enrolling 25 of 200 patients.”

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic — Subcutaneous

Indications

anemia cancer